VFA
PCRX icon

Valeo Financial Advisors’s Pacira BioSciences PCRX Stock Holding History

Valeo Financial Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-646
Closed -$45K – 1424
2021
Q1 		$45K Sell
646
-81
-11% -$5.79K ﹤0.01% 912
2020
Q4 		$44K Buy
727
+83
+13% +$4.86K ﹤0.01% 822
2020
Q3 		$39K Buy
644
+437
+211% +$25.4K ﹤0.01% 728
2020
Q2 		$11K Buy
207
+12
+6% +$502 ﹤0.01% 1254
2020
Q1 		$7K Hold
195
– – ﹤0.01% 1217
2019
Q4 		$9K Hold
195
– – ﹤0.01% 1146
2019
Q3 		$7K Buy
195
+64
+49% +$2.55K ﹤0.01% 1126
2019
Q2 		$6K Buy
131
+100
+323% +$4.25K ﹤0.01% 1163
2019
Q1 		$1K Hold
31
– – ﹤0.01% 1476
2018
Q4 		$1K Sell
31
-3
-9% -$140 ﹤0.01% 1403
2018
Q3 		$2K Hold
34
– – ﹤0.01% 1496
2018
Q2 		$2K Hold
34
– – ﹤0.01% 1365
2018
Q1 		$1K Hold
34
– – ﹤0.01% 1451
2017
Q4 		$2K Hold
34
– – ﹤0.01% 1197
2017
Q3 		$1K Buy
+34
New +$1.37K ﹤0.01% 1112

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Valeo Financial Advisors's PCRX Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Pacira BioSciences (PCRX) in Q2 2021, closing a stake of 646 shares — an estimated $45K sold.

Valeo Financial Advisors first reported a position in PCRX in Q3 2017 and held it in 15 quarters. The position peaked at $45K in Q1 2021. 262 funds tracked by Wall St. Rank hold PCRX as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Pacira BioSciences position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 646 Pacira BioSciences shares in Q2 2021, an estimated $45K.
  • Valeo Financial Advisors first reported a position in Pacira BioSciences in Q3 2017 and held it in 15 quarters.
  • Valeo Financial Advisors's Pacira BioSciences position peaked at $45K in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.